Pfizer Investor Guide & Business Dossier

Pfizer Inc. is one of the world's largest pharmaceutical companies, discovering, developing, manufacturing, and commercializing prescription medicines, vaccines, and consumer healthcare products. Pfizer's business is organized into two main commercial segments: Pfizer Innovative Health (innovative prescription drugs across oncology, immunology, cardiovascular/metabolic, rare disease, and hospital) and Pfizer Essential Health (off-patent generic pharmaceutical products and biosimilars). Key marketed products include Eliquis (apixaban, anticoagulant, co-promoted with Bristol-Myers Squibb and the world's best-selling oral anticoagulant), Ibrance (palbociclib, breast cancer CDK4/6 inhibitor), Prevnar vaccine franchise (pneumococcal vaccines, including Prevnar 20), Enbrel (etanercept, biologics for rheumatoid arthritis, co-promoted in some markets), Vyndaqel/Vyndamax (tafamidis, transthyretin amyloid cardiomyopathy), and historically Comirnaty (COVID-19 mRNA vaccine with BioNTech) and Paxlovid (nirmatrelvir/ritonavir, COVID-19 oral antiviral).

Pfizer generated extraordinary revenue from Comirnaty (the COVID-19 mRNA vaccine co-developed with BioNTech) and Paxlovid (its oral COVID antiviral) during 2021-2022. At peak, Comirnaty and Paxlovid combined contributed approximately $56 billion in revenue in 2022 -- representing over half of Pfizer's total revenue for the year. This peak was followed by a severe revenue normalization as global vaccination programs wound down, government stockpiling ended, and COVID transitioned from a pandemic emergency to an endemic seasonal disease. By 2023, COVID product revenue fell to approximately $12 billion and continued to decline. The collapse in COVID revenue created a 'COVID cliff' that left Pfizer with a revenue base in 2023-2024 substantially below 2022 levels, even as the underlying non-COVID business (Eliquis, Prevnar, oncology) continued to grow. The COVID windfall gave Pfizer approximately $30-40 billion in cash that it deployed primarily for the Seagen acquisition, making the strategic allocation of that capital one of the most significant investor-analyzed decisions in recent pharmaceutical M&A.

Pfizer acquired Seagen Inc. in December 2023 for approximately $43 billion, the largest acquisition in Pfizer's history. Seagen was a biotechnology company specializing in antibody-drug conjugates (ADCs), a cancer treatment modality that uses antibodies to deliver cytotoxic (cell-killing) payloads directly to cancer cells while sparing healthy tissue. ADCs have emerged as one of the most promising modalities in oncology, with multiple approved products and a crowded pipeline of candidates across tumor types. Seagen's approved products at acquisition included Adcetris (brentuximab vedotin, lymphoma), Padcev (enfortumab vedotin, urothelial cancer), Tukysa (tucatinib, HER2+ breast cancer), and Tivdak (tisotumab vedotin, cervical cancer). Pfizer's rationale was to acquire a leading ADC platform and pipeline at a point when the modality's clinical and commercial validity was established but before peak valuations were fully reflected -- deploying COVID cash into durable oncology assets before Eliquis and other products face patent cliffs. The Seagen acquisition significantly expands Pfizer's oncology presence and is expected to contribute meaningfully to revenue by the late 2020s.

Pfizer faces significant patent expirations in the coming years, most notably Eliquis (co-owned with Bristol-Myers Squibb, apixaban), which is expected to face generic competition in the U.S. beginning around 2026. Eliquis has generated approximately $6-7 billion in annual Pfizer revenue, making its LOE a material headwind. Ibrance (palbociclib, CDK4/6 inhibitor for breast cancer) faces biosimilar competition risk in the coming years. To offset these pressures, Pfizer's pipeline priorities include its obesity/GLP-1 oral program (competing in the high-profile weight loss drug market dominated by Novo Nordisk's semaglutide and Eli Lilly's tirzepatide), additional ADC oncology programs through Seagen, respiratory and vaccine programs (RSV vaccines, next-generation Prevnar formulations), and antivirals. The obesity drug market represents a significant potential revenue opportunity for Pfizer if its oral GLP-1 agonist achieves competitive efficacy -- Pfizer had earlier GLP-1 program failures, but oral small molecule obesity drugs are a genuine unmet need given the injection-based market leaders.

Key risks include Eliquis patent cliff (Eliquis contributes approximately $6-7B in annual Pfizer revenue; generic entry around 2026 creates a significant revenue headwind just as Pfizer needs pipeline products to offset COVID normalization), Seagen integration execution (a $43B acquisition requires successful integration of Seagen's commercial and development organizations; ADC pipeline programs must advance and compete effectively in a now-crowded ADC market where Daiichi Sankyo/AstraZeneca and others have very strong programs), COVID revenue normalization (COVID product revenue continues to decline from its 2022 peak; the remaining COVID revenue is highly sensitive to annual vaccination take-up rates, which are difficult to predict), GLP-1/obesity competition (Pfizer has an oral GLP-1 program but faces formidable competition from Novo Nordisk and Eli Lilly; failing to compete in this market would eliminate a major potential growth driver), dividend sustainability (Pfizer's dividend has been covered by earnings historically, but COVID cliff revenue loss plus Seagen acquisition debt have compressed near-term free cash flow; investors monitor whether the current dividend rate is maintainable), and pipeline execution risk (pharmaceutical pipeline success rates are inherently low; major late-stage failures in oncology or any other high-priority area would reset growth expectations).